Pallidal activity as a driving force of choreic movements
Objective: To investigate the mechanisms of neuronal discharges of the globus pallidus which drive choreic movements. Background: Synchronized bursts and the low discharge rates of…Effects of cerebellar cTBS on motor symptoms in Huntington’s disease: a feasibility and pilot study
Objective: To evaluate the feasibility and preliminary clinical effects of a single session of cerebellar cTBS in patients with Huntington's disease (HD) with mild-moderate motor…Localisation of distinct brain networks in premanifest and manifest Huntington’s disease
Objective: To map the brain networks underlying Huntington’s Disease (HD), testing whether there are distinct networks involved in premanifest and manifest disease stages. Background: HD…Autoimmune Chorea. Therapy with Monoclonal Antibodies: Experimental and Clinical Approach
Objective: Autoimmune chorea (AICh) resulting from the appearance of paraneoplastic antibodies in response to development of malignant tumors of various localization. Sydenham's rheumatic chorea, described…Reversible hemichorea due to contralateral anterior cerebral artery territory hypoperfusion
Objective: We report hemichorea due to hypoperfusion of the contralateral anterior cerebral artery (ACA) territory (including caudate nucleus and its connections) that reversed with revascularization.…Neural oscillations modulation during working memory in premanifest and early Huntington’s disease
Objective: To test whether high-density electroencephalography (hdEEG) coupled to source localization allows for the identification of neuronal oscillations in specific frequency bands in patients with…Evaluation of CSF Assay usability for Huntington’s Disease (HD) Clinical Studies (mHTT, tHTT and NFL in HDClarity)
Objective: Evaluate clinical utility of candidate biomarker assays for HD studies. Background: Multiple clinical trials targeting the lowering of huntingtin (HTT) are underway or planned.…Diabetes Mellitus in Huntington’s disease. The Argentinean perspective
Objective: to compare the prevalence of diabetes mellitus (DM) in a self-reported series of local Huntington disease (HD) participants in the ENROLL-HD registry with the…Risk and timing of manifest Huntington’s disease in patients with reduced penetrance alleles
Objective: To estimate risk of Huntington’s disease (HD) over time in patients with reduced penetrance (RP) alleles (36-39 CAG repeats) overall, by individual repeat length,…Validation of biomarkers in Huntington’s disease to support the development of disease-modifying therapies: a systematic review and critical appraisal scheme
Objective: To review studies for disease progression biomarkers published in HD and evaluate their methodological quality in a standardized manner. Background: Huntington disease (HD) is a fatal autosomal dominant neurodegenerative condition that starts to manifest clinically around the 4th decade of life. There are promising novel genetic-based therapies under development intended to modify the disease trajectory. Valid…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.